Aberrant Signalling In Leukaemia
Grant number: 1071897 | Funding period: 2018 - 2019
This Program studies the mechanisms that control blood cell formation and how abnormalities play a role in leukaemia, a significant health problem worldwide. Despite some improvements, two major problems remain: controlling progression of leukaemia and relapse. The Program tackles these two major issues with the combination of studies of normal blood and leukaemia cell function, drug design and clinical trials ensuring a direct pathway from discovery to patient benefit.
Related publications (2)
EPO does not promote interaction between the erythropoietin and beta-common receptors (vol 8, 12457, 2018)
Karen S Cheung Tung Shing, Sophie E Broughton, Tracy L Nero, Kevin Gillinder, Melissa D Ilsley, Hayley Ramshaw, Angel F Lopez, Michael DW Griffin, Michael W Parker, Andrew C Perkins, Urmi Dhagat